This study tests if apixaban (a blood thinner) is better than aspirin for preventing strokes or death in patients who had a recent intracerebral hemorrhage (ICH), which is bleeding in the brain, and atrial fibrillation (AF), an irregular heartbeat. The study will also see if apixaban improves recovery based on a scale called the modified Rankin Scale, which measures how well a person can do daily activities after a stroke. Seven hundred participants will be followed for 1 to 3 years. To join, participants must be 18 or older, have recently experienced ICH, and have AF. Some reasons you might not join include having other medical conditions like active infections, certain bleeding disorders, or if you're pregnant. The study is part of a larger network coordinated by the NIH/NINDS, which are organizations that focus on neurological health.

• Duration: Participate for 1 to 3 years.
• Visits: Multiple visits required over study period.
• Considerations: Ensure no conflicting health issues or current treatments.